Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...
SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...
Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...
ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results